These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16515497)

  • 1. Immunotherapy for prostate cancer.
    Karnes RJ; Whelan CM; Kwon ED
    Curr Pharm Des; 2006; 12(7):807-17. PubMed ID: 16515497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer: advances in immunotherapy.
    Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED
    BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
    Thompson RH; Allison JP; Kwon ED
    Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer immunology: biology, therapeutics, and challenges.
    Webster WS; Small EJ; Rini BI; Kwon ED
    J Clin Oncol; 2005 Nov; 23(32):8262-9. PubMed ID: 16278482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
    Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
    Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E
    Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer immunotherapy: where are we and where are we going?
    De Velasco MA; Uemura H
    Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for prostate cancer.
    Markiewicz MA; Kast WM
    Adv Cancer Res; 2003; 87():159-94. PubMed ID: 12641276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.
    Kwon ED; Hurwitz AA; Foster BA; Madias C; Feldhaus AL; Greenberg NM; Burg MB; Allison JP
    Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8099-103. PubMed ID: 9223321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of immunotherapy in the management of prostate cancer.
    Slovin SF
    Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.